(Q40070563)

English

Rationale and clinical implication of combined chemotherapy with cisplatin and oestrogen in prostate cancer: primary evidence based on methylation analysis of oestrogen receptor-alpha

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Rationale and clinical implication of combined chemotherapy with cisplatin and oestrogen in prostate cancer: primary evidence based on methylation analysis of oestrogen receptor-alpha (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Nobuko Moriyama-Gonda

1

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Hiroaki Shiina

2

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Masaharu Terashima

3

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Kazumi Satoh

4

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Mikio Igawa

5

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

publication date

8 October 2007

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

BJU International

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

101

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

485-491

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07256.X

21 January 2018

Structure, Recognition, and Processing of Cisplatin-DNA Adducts.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07256.X

21 January 2018

Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07256.X

21 January 2018

HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07256.X

21 January 2018

High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07256.X

21 January 2018

HMG1 and 2, and related 'architectural' DNA-binding proteins

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07256.X

21 January 2018

New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07256.X

21 January 2018

Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07256.X

21 January 2018

Identifiers

10.1111/J.1464-410X.2007.07256.X

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40070563&oldid=1883619374"